Illumina, Inc. $ILMN Shares Purchased by Stephens Investment Management Group LLC

Stephens Investment Management Group LLC increased its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 13.7% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 389,354 shares of the life sciences company’s stock after purchasing an additional 46,783 shares during the period. Stephens Investment Management Group LLC’s holdings in Illumina were worth $47,992,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Elyxium Wealth LLC acquired a new position in shares of Illumina in the fourth quarter worth $25,000. Board of the Pension Protection Fund acquired a new stake in shares of Illumina in the fourth quarter valued at $26,000. Creative Capital Management Investments LLC raised its stake in shares of Illumina by 160.0% in the fourth quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock valued at $26,000 after acquiring an additional 120 shares in the last quarter. TD Waterhouse Canada Inc. purchased a new position in Illumina in the fourth quarter valued at $26,000. Finally, Laurel Wealth Advisors LLC purchased a new position in Illumina in the fourth quarter valued at $26,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ILMN has been the topic of several recent research reports. JPMorgan Chase & Co. upgraded Illumina from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $125.00 to $185.00 in a report on Wednesday, June 10th. Citigroup boosted their price objective on Illumina from $80.00 to $95.00 and gave the stock a “sell” rating in a research report on Monday, May 4th. Wall Street Zen cut shares of Illumina from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Canaccord Genuity Group decreased their price target on shares of Illumina from $150.00 to $140.00 and set a “hold” rating for the company in a research note on Friday, May 1st. Finally, Guggenheim boosted their price target on shares of Illumina from $180.00 to $200.00 and gave the stock a “buy” rating in a report on Monday, June 29th. Eight equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Illumina currently has a consensus rating of “Hold” and an average target price of $148.94.

Insider Activity at Illumina

In other Illumina news, CAO Scott D. Ericksen sold 500 shares of the firm’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $160.00, for a total transaction of $80,000.00. Following the transaction, the chief accounting officer owned 14,446 shares of the company’s stock, valued at approximately $2,311,360. This trade represents a 3.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 235,000 shares of the business’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $163.63, for a total value of $38,453,050.00. Following the completion of the sale, the director directly owned 2,830,452 shares of the company’s stock, valued at $463,146,860.76. The trade was a 7.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 1,003,769 shares of company stock valued at $155,710,908 over the last quarter. 2.90% of the stock is owned by insiders.

Illumina Price Performance

Shares of NASDAQ ILMN opened at $188.68 on Friday. The business has a 50-day moving average of $154.74 and a two-hundred day moving average of $139.42. The company has a market capitalization of $28.55 billion, a price-to-earnings ratio of 34.31, a price-to-earnings-growth ratio of 3.53 and a beta of 1.47. Illumina, Inc. has a 1 year low of $88.00 and a 1 year high of $189.46. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.75 and a quick ratio of 1.36.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.05 by $0.10. The business had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The business’s quarterly revenue was up 4.8% on a year-over-year basis. During the same quarter last year, the company earned $0.97 EPS. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. On average, analysts forecast that Illumina, Inc. will post 5.21 earnings per share for the current fiscal year.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.